Market closed

AlloVir/ALVR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AlloVir

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Ticker

ALVR
Trading on

Industry

Biotechnology

Employees

8

AlloVir Metrics

BasicAdvanced
$90M
Market cap
-
P/E ratio
-$1.23
EPS
0.77
Beta
-
Dividend rate
$90M
0.77
$2.49
$0.58
169K
55.082
54.984
6.93
7.484
-36.53%
-80.33%
0.74
0.74
-0.744
-32.70%
-15.93%

What the Analysts think about AlloVir

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for AlloVir stock.

AlloVir Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AlloVir Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ALVR

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AlloVir stock?

AlloVir (ALVR) has a market cap of $90M as of October 08, 2024.

What is the P/E ratio for AlloVir stock?

The price to earnings (P/E) ratio for AlloVir (ALVR) stock is 0 as of October 08, 2024.

Does AlloVir stock pay dividends?

No, AlloVir (ALVR) stock does not pay dividends to its shareholders as of October 08, 2024.

When is the next AlloVir dividend payment date?

AlloVir (ALVR) stock does not pay dividends to its shareholders.

What is the beta indicator for AlloVir?

AlloVir (ALVR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.